The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an single arm, open-label, phase II trial to evaluate safety and efficacy of using
the combination of Camrelizumab with apatinib as second-line therapy for advanced PDAC.